JP2015500329A5 - - Google Patents

Download PDF

Info

Publication number
JP2015500329A5
JP2015500329A5 JP2014546672A JP2014546672A JP2015500329A5 JP 2015500329 A5 JP2015500329 A5 JP 2015500329A5 JP 2014546672 A JP2014546672 A JP 2014546672A JP 2014546672 A JP2014546672 A JP 2014546672A JP 2015500329 A5 JP2015500329 A5 JP 2015500329A5
Authority
JP
Japan
Prior art keywords
buprenorphine
transdermal therapeutic
therapeutic system
hours
adhesive layer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014546672A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015500329A (ja
JP6289378B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2012/002973 external-priority patent/WO2013088254A1/en
Publication of JP2015500329A publication Critical patent/JP2015500329A/ja
Publication of JP2015500329A5 publication Critical patent/JP2015500329A5/ja
Application granted granted Critical
Publication of JP6289378B2 publication Critical patent/JP6289378B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014546672A 2011-12-12 2012-12-12 ブプレノルフィンを含む経皮送達システム Active JP6289378B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161569609P 2011-12-12 2011-12-12
US61/569,609 2011-12-12
PCT/IB2012/002973 WO2013088254A1 (en) 2011-12-12 2012-12-12 Transdermal delivery system comprising buprenorphine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016198650A Division JP2017036304A (ja) 2011-12-12 2016-10-07 ブプレノルフィンを含む経皮送達システム

Publications (3)

Publication Number Publication Date
JP2015500329A JP2015500329A (ja) 2015-01-05
JP2015500329A5 true JP2015500329A5 (enExample) 2015-03-12
JP6289378B2 JP6289378B2 (ja) 2018-03-07

Family

ID=47754872

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014546672A Active JP6289378B2 (ja) 2011-12-12 2012-12-12 ブプレノルフィンを含む経皮送達システム
JP2016198650A Pending JP2017036304A (ja) 2011-12-12 2016-10-07 ブプレノルフィンを含む経皮送達システム

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016198650A Pending JP2017036304A (ja) 2011-12-12 2016-10-07 ブプレノルフィンを含む経皮送達システム

Country Status (26)

Country Link
US (4) US20140363487A1 (enExample)
EP (1) EP2790685B2 (enExample)
JP (2) JP6289378B2 (enExample)
KR (1) KR102014565B1 (enExample)
CN (2) CN104114161A (enExample)
AP (1) AP4036A (enExample)
AR (1) AR089201A1 (enExample)
AU (1) AU2012327247B2 (enExample)
BR (1) BR112014014137A2 (enExample)
CA (1) CA2858531C (enExample)
CL (1) CL2014001559A1 (enExample)
CO (1) CO7000779A2 (enExample)
CR (1) CR20140321A (enExample)
DE (1) DE112012005185T5 (enExample)
EA (1) EA201491164A1 (enExample)
ES (1) ES2647516T5 (enExample)
GB (1) GB2512007B8 (enExample)
IL (1) IL233025A0 (enExample)
MX (1) MX352795B (enExample)
PE (1) PE20142341A1 (enExample)
PH (1) PH12014501231A1 (enExample)
PL (1) PL2790685T3 (enExample)
SG (2) SG10201604754VA (enExample)
TN (1) TN2014000233A1 (enExample)
TW (1) TW201338813A (enExample)
WO (1) WO2013088254A1 (enExample)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
DE102006054731B4 (de) 2006-11-21 2013-02-28 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System zur Verabreichung des Wirkstoffs Buprenorphin und Verwendung desselben in der Schmerztherapie
EP2152315B1 (en) 2007-05-25 2016-01-06 Indivior UK Limited Sustained delivery formulations of risperidone compounds
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
GB2513060B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
US20130017259A1 (en) 2011-07-06 2013-01-17 The Parkinson's Institute Compositions and Methods for Treatment of Symptoms in Parkinson's Disease Patients
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
EP2782584B1 (en) 2011-11-23 2021-06-09 TherapeuticsMD, Inc. Natural combination hormone replacement formulations and therapies
CA2856196C (en) 2011-12-06 2020-09-01 Masco Corporation Of Indiana Ozone distribution in a faucet
EA201491164A1 (ru) 2011-12-12 2014-10-30 ЭлТиЭс ЛОМАНН ТЕРАПИ-ЗЮСТЕМ АГ Трансдермальная система доставки
WO2013126552A1 (en) * 2012-02-21 2013-08-29 Auburn University Buprenorphine nanoparticle composition and methods thereof
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
TW201431570A (zh) 2012-11-22 2014-08-16 Ucb Pharma Gmbh 用於經皮投服羅替戈汀(Rotigotine)之多天式貼片
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10105487B2 (en) 2013-01-24 2018-10-23 Chrono Therapeutics Inc. Optimized bio-synchronous bioactive agent delivery system
WO2014195352A1 (en) 2013-06-04 2014-12-11 Lts Lohmann Therapie-Systeme Ag Transdermal delivery system
CN105358139B (zh) 2013-07-03 2020-10-16 Lts罗曼治疗方法有限公司 具有电子元件的经皮治疗系统
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
JP6573913B2 (ja) 2014-05-20 2019-09-11 エルテーエス ローマン テラピー−ジステーメ アーゲー ロチゴチンを含む経皮送達システム
CN106456567A (zh) 2014-05-20 2017-02-22 Lts勒曼治疗系统股份公司 在经皮递送系统中调节活性剂释放的方法
ES2954087T3 (es) 2014-05-20 2023-11-20 Lts Lohmann Therapie Systeme Ag Sistema de administración transdérmica que incluye un mediador de interfase
AR100562A1 (es) 2014-05-22 2016-10-12 Therapeuticsmd Inc Composición farmacéutica de estradiol y progesterona para terapia de reemplazo hormonal
JP2018511355A (ja) 2015-01-28 2018-04-26 クロノ セラピューティクス インコーポレイテッドChrono Therapeutics Inc. 薬剤送達方法及びシステム
CN107660207B (zh) * 2015-03-10 2020-09-29 罗德科技公司 丁丙诺啡乙酸盐及用于制备丁丙诺啡的方法
AU2016228779A1 (en) 2015-03-12 2017-09-07 Chrono Therapeutics Inc. Craving input and support system
EP3067050A1 (en) 2015-03-13 2016-09-14 Acino AG Transdermal therapeutic system with an overtape comprising two adhesive layers
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
EP3349737A4 (en) * 2015-09-14 2019-05-15 Amneal Pharmaceuticals LLC SYSTEM FOR TRANSDERING
US11458214B2 (en) 2015-12-21 2022-10-04 Delta Faucet Company Fluid delivery system including a disinfectant device
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
KR20180126582A (ko) 2016-04-01 2018-11-27 쎄러퓨틱스엠디, 인코퍼레이티드 스테로이드 호르몬 약제학적 조성물
WO2018129304A1 (en) 2017-01-06 2018-07-12 Chrono Therapeutics Inc. Transdermal drug delivery devices and methods
WO2019064026A1 (en) 2017-09-29 2019-04-04 Orexo Ab NEW PHARMACEUTICAL COMPOSITIONS
GB201716830D0 (en) 2017-10-13 2017-11-29 Cambrex Charles City Inc New Process
BR112020018300A2 (pt) 2018-03-13 2020-12-22 Lts Lohmann Therapie-Systeme Ag Sistema terapêutico transdérmico compreendendo um polímero híbrido de silicone e acrílico
CA3092752A1 (en) 2018-03-13 2019-09-19 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system comprising a silicone acrylic hybrid polymer
WO2019175101A1 (en) 2018-03-13 2019-09-19 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system comprising a silicone acrylic hybrid polymer
AU2019279884B2 (en) 2018-05-29 2025-01-30 Morningside Venture Investments Limited Drug delivery methods and systems
JP2022507660A (ja) 2018-11-16 2022-01-18 モーニングサイド ベンチャー インベストメンツ リミテッド 温度によって調節される経皮薬剤送達システム
GB201904767D0 (en) 2019-04-04 2019-05-22 Orexo Ab New pharmaceutical compositions
CN113952319A (zh) * 2021-11-30 2022-01-21 烟台大学 一种含丁丙诺啡的骨架型透皮贴剂及其制备方法
CN114397411A (zh) * 2021-12-14 2022-04-26 苏州高迈药业有限公司 一种评价利丙双卡因乳膏的方法
WO2024040897A1 (zh) * 2022-08-24 2024-02-29 新领医药技术(深圳)有限公司 沙利度胺或其类似物透皮贴剂及其制备方法

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US119585A (en) * 1871-10-03 Improvement in horse-collars and hames
GB1136214A (en) 1965-06-15 1968-12-11 Reckitt & Sons Ltd Thebaine and oripavine derivatives
US3474101A (en) 1960-09-05 1969-10-21 Reckitt & Sons Ltd Thebaine and oripavine derivatives
US4806341A (en) 1985-02-25 1989-02-21 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration
CA2002299A1 (en) 1988-11-10 1990-05-10 Eugene G. Drust Compositions for the transdermal delivery of buprenorphine salts
DE3939376C1 (enExample) 1989-11-29 1991-05-08 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg, 5450 Neuwied, De
US5240711A (en) 1989-11-29 1993-08-31 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Transdermal therapeutic system comprising as active component buprenorphine
US5069909A (en) 1990-06-20 1991-12-03 Cygnus Therapeutic Systems Transdermal administration of buprenorphine
US5635203A (en) * 1994-09-29 1997-06-03 Alza Corporation Transdermal device having decreased delamination
DE4446600A1 (de) 1994-12-24 1996-06-27 Lohmann Therapie Syst Lts Transdermale Resorption von Wirkstoffen aus unterkühlten Schmelzen
US5968547A (en) 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
DE19922662C1 (de) 1999-05-18 2000-12-28 Sanol Arznei Schwarz Gmbh Transdermales therapeutisches System (TTS) Tolterodin enthaltend
CA2374930C (en) 1999-07-02 2008-08-05 Lts Lohmann Therapie-Systeme Ag Microreservoir system based on polysiloxanes and ambiphilic solvents
DE19958554C2 (de) 1999-07-02 2002-06-13 Lohmann Therapie Syst Lts Mikroreservoirsystem auf Basis von Polysiloxanen und ambiphilen Lösemitteln und ihre Herstellung
WO2001014336A1 (en) * 1999-08-20 2001-03-01 Nippon Kayaku Kabushiki Kaisha Benzene derivatives substituted by aromatic ring and process for producing the same
SI2283842T1 (sl) 2000-02-08 2015-07-31 Euro-Celtique S.A. Oralne formulacije opioidnih agonistov, varne pred zlorabo
JP4659943B2 (ja) * 2000-02-25 2011-03-30 帝三製薬株式会社 塩酸ブプレノルフィン含有貼付剤
US6844727B2 (en) * 2000-06-28 2005-01-18 Baker Hughes Incorporated Method and apparatus of reducing ringing in a nuclear magnetic resonance probe
US6682757B1 (en) 2000-11-16 2004-01-27 Euro-Celtique, S.A. Titratable dosage transdermal delivery system
WO2002083135A2 (en) 2001-02-16 2002-10-24 Grünenthal GmbH Use of buprenorphine for the manufacture of a transdermal delivery device for the treatment of urinary incontinence, especially urge incontinence
DE10141651B4 (de) 2001-08-24 2007-02-15 Lts Lohmann Therapie-Systeme Ag Transdermales Therapeutisches System (TTS) mit dem Wirkstoff Fentanyl und Verfahren zu seiner Herstellung
US20050118245A1 (en) 2002-03-27 2005-06-02 Wilsmann Klaus M. Assembled unit consisting of individually separable, transdermal, therapeutic systems
DE10213772A1 (de) 2002-03-27 2003-10-09 Gruenenthal Gmbh Zusammenhängende Einheit aus vereinzelbaren transdermalen therapeutischen Systemen
PT1526848E (pt) * 2002-08-09 2007-08-08 Gruenenthal Gmbh Antagonistas dos receptores de opióides em sistemas transdérmicos contendo buprenorfina
US20050191340A1 (en) * 2002-08-09 2005-09-01 Gruenenthal Gmbh Opioid-receptor antagonists in transdermal systems having buprenorphine
US7270830B2 (en) 2002-12-13 2007-09-18 Purdue Pharma L.P. Transdermal buprenorphine dosage regimen for analgesia
RU2324372C2 (ru) 2003-03-25 2008-05-20 Моринда, Инк. Селективное ингибирование продукции эстрогена и обеспечение эстрогенного действия в организме человека
US7182955B2 (en) * 2003-04-30 2007-02-27 3M Innovative Properties Company Abuse-resistant transdermal dosage form
US8790689B2 (en) * 2003-04-30 2014-07-29 Purdue Pharma L.P. Tamper resistant transdermal dosage form
DE102004045599A1 (de) 2004-09-17 2006-03-23 Grünenthal GmbH System zur sequentiellen, transdermalen Verabreichung von systemisch wirksamen Substanzen
DE102004062647A1 (de) 2004-12-21 2006-06-29 Kronotec Ag Holzfaserdämmstoffplatte bzw.- matte
DE102004062614B4 (de) 2004-12-24 2011-12-29 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System mit aktivierbarer Übersättigung und kontrollierter Permeationförderung sowie Verfahren zu dessen Herstellung
DE102006054731B4 (de) * 2006-11-21 2013-02-28 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System zur Verabreichung des Wirkstoffs Buprenorphin und Verwendung desselben in der Schmerztherapie
DE102006054732B4 (de) 2006-11-21 2010-12-30 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System mit Ionenpaar-Mikroreservoiren
EP2366388A1 (de) 2010-03-17 2011-09-21 Ratiopharm GmbH Nicht-okklusives transdermales therapeutisches System zur Verabreichung von Buprenorphin
EA201491164A1 (ru) * 2011-12-12 2014-10-30 ЭлТиЭс ЛОМАНН ТЕРАПИ-ЗЮСТЕМ АГ Трансдермальная система доставки
AU2013205080B2 (en) 2012-12-12 2016-07-07 Lts Lohmann Therapie-Systeme Ag Transdermal Delivery System
WO2014195352A1 (en) 2013-06-04 2014-12-11 Lts Lohmann Therapie-Systeme Ag Transdermal delivery system

Similar Documents

Publication Publication Date Title
CN101528207B (zh) 用于活性物质丁丙诺啡的给药的透皮治疗系统
US8246976B2 (en) Transdermal delivery of drugs based on crystal size
US5306503A (en) Patch with a high content of softening ingredients
JP2016502989A5 (enExample)
JP5591685B2 (ja) 経皮吸収製剤
JP2016520638A5 (enExample)
US9717697B2 (en) Compositions and methods for the transdermal delivery of methylphenidate
KR101853082B1 (ko) 활성제층 및 활성제 변환층을 포함하는 경피 조성물
CA2896055C (en) Compositions and methods for transdermal delivery of amphetamine and clonidine
US20180256562A1 (en) Transdermal Delivery System
CN105377245B (zh) 透皮递送系统
US9700522B2 (en) Transdermal patch and method for delivery of vitamin B12
CA2896336C (en) Compositions and methods for transdermal delivery of non-steroidal anti-inflammatory agents
CN104144684A (zh) 含有多奈哌齐的经皮吸收制剂及其制备方法
WO2014159573A1 (en) Methylphenidate transdermal compositions with rubber-based adhesives
US20170112781A1 (en) Transdermal drug delivery systems with polyisobutylene face adhesive
WO2013047410A1 (ja) 持続型アルツハイマー病治療用貼付剤及びその製造方法
ES2872725T3 (es) Sistema terapéutico transdérmico con una sobrecubierta que comprende dos capas adhesivas
CN108785286A (zh) 透皮吸收制剂
EP2914249A1 (en) Propynylaminoindan transdermal compositions
CN102895217A (zh) 长效多奈哌齐经皮吸收贴剂
JP2004256396A (ja) 低皮膚刺激性硬膏剤
KR101353478B1 (ko) 펜타닐을 함유하는 경피투여용 패취 제제
WO2014159778A1 (en) Transdermal drug delivery system containing fentanyl
HK1187817B (en) Transdermal compositions comprising an active agent layer and an active agent conversion layer